tiprankstipranks
Revive Therapeutics Advances Research on Bucillamine for Nerve Agent Exposure
PremiumCompany AnnouncementsRevive Therapeutics Advances Research on Bucillamine for Nerve Agent Exposure
3M ago
Revive Therapeutics provides update on research study of bucillamine
Premium
The Fly
Revive Therapeutics provides update on research study of bucillamine
3M ago
Revive Therapeutics announces publication on potential of psilocybin
Premium
The Fly
Revive Therapeutics announces publication on potential of psilocybin
5M ago
Revive Therapeutics Explores Bucillamine for Nerve Agents and Viral Threats
PremiumCompany AnnouncementsRevive Therapeutics Explores Bucillamine for Nerve Agents and Viral Threats
7M ago
Revive Therapeutics provides information update on Bucillamine and Mpox
Premium
The Fly
Revive Therapeutics provides information update on Bucillamine and Mpox
7M ago
Revive Therapeutics Tests Treatment for Nerve Agents
Premium
Company Announcements
Revive Therapeutics Tests Treatment for Nerve Agents
9M ago
Revive Therapeutics Advances Long COVID Treatment
PremiumCompany AnnouncementsRevive Therapeutics Advances Long COVID Treatment
11M ago
Revive Therapeutics granted Type C meeting request by FDA for bucillamine
Premium
The Fly
Revive Therapeutics granted Type C meeting request by FDA for bucillamine
11M ago
Revive Therapeutics Advances Long COVID Diagnostic
Premium
Company Announcements
Revive Therapeutics Advances Long COVID Diagnostic
11M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100